Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 5,570 shares at $80.80 ($449K) on 2022-02-07, disclosed to the SEC on 2022-02-09.
Open-market sale of $449k NBIX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $80.78 | 1,280 | $103K | 23.0% |
| 2 | $80.78 | 1,280 | $103K | 23.0% |
| 3 | $80.80 | 2,030 | $164K | 36.5% |
| 4 | $79.65 | 980 | $78K | 17.4% |
| Total | $80.59 avg | 5,570 | $449K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-08-15 | $2.1M | — | Filing → |